Two of our CUSP9 drugs- disulfiram and ritonavir/nelfinavir have a potential synergy in inhibiting a growth path used in glioblastoma that resembles closely an IL-1beta converting enzyme (ICE-1, also termed caspase-1) and IL-18 mediated inflammation paths in some cases of acute pancreatitis [153], diagramed in Fig. 4. Here, CASP1 is linked to acute pancreatitis.